Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2020-11-17 Interim / Quarterly Rep…
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the three and nine months ended September 30, 2020 and 2019. It contains detailed discussion of the company's financial condition, business strategy, risks, and operational results for an interim period. The presence of forward-looking statements, risk factors, and detailed business overview aligns with typical MD&A content. The document references unaudited interim condensed consolidated financial statements for the same periods, indicating it accompanies an interim report. The length (15,000 characters) and content indicate this is a substantive financial report, not merely an announcement or certification. Therefore, the document is best classified as an Interim / Quarterly Report (IR). 9M 2020
2020-11-17 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CEO of Trillium Therapeutics Inc. regarding the interim financial report and interim MD&A for the period ended September 30, 2020. It is a Form 52-109F2 certification, which is a regulatory attestation of the accuracy and completeness of the interim filings. The document does not contain actual financial statements or substantive financial data but rather certifies the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3301 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-11-17 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE' signed by the CFO of Trillium Therapeutics Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2020. The document contains no actual financial data or analysis but is an officer certification regarding the interim filings. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is 3312 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-11-17 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report from Trillium Therapeutics reporting its third quarter 2020 financial and operating results. It includes comprehensive financial data such as consolidated statements of loss and financial position, detailed discussion of clinical study updates, financing activities, governance changes, and forward-looking statements. The presence of actual financial statements and substantive financial data for a quarterly period (nine months ended September 30, 2020) indicates this is a financial report for a period shorter than a full fiscal year. The document is not merely an announcement or a press release of earnings highlights but contains detailed financial and operational information. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-11-16 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is an announcement about the appointment of Paolo Pucci to the Board of Directors of Trillium Therapeutics. It focuses on management changes and does not contain financial data, report content, or regulatory filings. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2020-11-12 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new Chief Medical Officer at Trillium Therapeutics. It contains no financial data, no regulatory form references, no voting results, no legal proceedings, no capital changes, and no report publication statements. It is a management change announcement. Therefore, it fits the category of Board/Management Information (MANG). The document length is 5686 characters, which is sufficient for a detailed announcement. There is no indication that this is a report or a regulatory filing. Hence, the classification is MANG with high confidence.
2020-11-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.